Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial

Por Ferenci, Peter, Caruntu, Florin A., Lengyel, Gabriella, Messinger, Diethelm, Bakalos, Georgios, Flisiak, Robert
Publicado no Infect Dis Ther (2016)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin

Por Asselah, Tarik, Thompson, Alex J., Flisiak, Robert, Romero-Gomez, Manuel, Messinger, Diethelm, Bakalos, Georgios, Shiffman, Mitchell L.
Publicado no PLoS One (2016)

IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C stud...

Por Mangia, Alessandra, De Ledinghen, Victor, Bailly, François, Brahm, Javier, Keiss, Jazeps, Valantinas, Jonas, Rasmann, Nele, Messinger, Diethelm, Tatsch, Fernando, Bakalos, Georgios, Foster, Graham R.
Publicado no Springerplus (2016)

Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort

Por Foster, Graham R., Coppola, Carmine, Derbala, Moutaz, Ferenci, Peter, Orlandini, Alessandra, Reddy, K. Rajender, Tallarico, Ludovico, Shiffman, Mitchell L., Ahlers, Silke, Bakalos, Georgios, Hassanein, Tarek
Publicado no PLoS One (2016)